Our bispecific antibody armed activated T-cell (BAT) approach using anti-CD3 × anti-CD33 BiAb (CD33GOBi) redirected T cells (CD33GO BATs) or anti-CD3 × anti-CD123 BiAb (CD123Bi) redirected T cells (CD123 BATs) may improve outcomes for patients with AML without cytokine release syndrome (CRS) and may enhance chemo-responsiveness of chemo-resistant cells in a non-MHC restricted manner. The gene discussed is CD33; the disease is acute myeloid leukemia.